DekaBank Deutsche Girozentrale Increases Stock Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

DekaBank Deutsche Girozentrale lifted its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 11.9% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 224,185 shares of the biopharmaceutical company's stock after acquiring an additional 23,795 shares during the quarter. DekaBank Deutsche Girozentrale owned about 0.21% of Regeneron Pharmaceuticals worth $196,269,000 as of its most recent filing with the SEC.

Several other large investors also recently made changes to their positions in the stock. Sunbelt Securities Inc. bought a new stake in Regeneron Pharmaceuticals during the 1st quarter valued at approximately $25,000. Annis Gardner Whiting Capital Advisors LLC bought a new stake in Regeneron Pharmaceuticals during the 3rd quarter valued at approximately $26,000. Fortitude Family Office LLC bought a new stake in Regeneron Pharmaceuticals during the 4th quarter valued at approximately $31,000. Sutton Wealth Advisors Inc. boosted its stake in Regeneron Pharmaceuticals by 38.2% during the 3rd quarter. Sutton Wealth Advisors Inc. now owns 47 shares of the biopharmaceutical company's stock valued at $39,000 after purchasing an additional 13 shares during the period. Finally, Bruce G. Allen Investments LLC bought a new stake in Regeneron Pharmaceuticals during the 4th quarter valued at approximately $40,000. Institutional investors own 83.31% of the company's stock.

Analyst Upgrades and Downgrades

Several analysts recently weighed in on REGN shares. Cantor Fitzgerald increased their target price on Regeneron Pharmaceuticals from $850.00 to $925.00 and gave the company a "neutral" rating in a research note on Tuesday, February 6th. Royal Bank of Canada increased their price objective on shares of Regeneron Pharmaceuticals from $1,096.00 to $1,184.00 and gave the company an "outperform" rating in a research note on Tuesday, February 27th. Sanford C. Bernstein assumed coverage on shares of Regeneron Pharmaceuticals in a research report on Tuesday, March 12th. They set an "outperform" rating and a $1,125.00 target price on the stock. StockNews.com cut shares of Regeneron Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a research note on Friday, January 5th. Finally, Morgan Stanley lifted their price objective on Regeneron Pharmaceuticals from $1,104.00 to $1,115.00 and gave the company an "overweight" rating in a report on Wednesday, March 13th. Four research analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company's stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average target price of $968.43.

Regeneron Pharmaceuticals Trading Up 0.6 %

Shares of Regeneron Pharmaceuticals stock traded up $5.68 on Friday, hitting $942.70. 354,446 shares of the company's stock traded hands, compared to its average volume of 408,818. The firm's 50-day moving average price is $959.92 and its two-hundred day moving average price is $886.01. The stock has a market capitalization of $103.47 billion, a PE ratio of 27.13, a price-to-earnings-growth ratio of 2.75 and a beta of 0.11. Regeneron Pharmaceuticals, Inc. has a one year low of $684.80 and a one year high of $998.33. The company has a debt-to-equity ratio of 0.10, a current ratio of 5.69 and a quick ratio of 4.94.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last issued its earnings results on Friday, February 2nd. The biopharmaceutical company reported $11.86 EPS for the quarter, beating the consensus estimate of $10.73 by $1.13. The company had revenue of $3.43 billion during the quarter, compared to analysts' expectations of $3.29 billion. Regeneron Pharmaceuticals had a net margin of 30.14% and a return on equity of 17.61%. The business's revenue for the quarter was up .6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $10.96 EPS. On average, research analysts expect that Regeneron Pharmaceuticals, Inc. will post 38.18 EPS for the current fiscal year.

Insider Activity at Regeneron Pharmaceuticals

In related news, EVP Andrew J. Murphy sold 5,783 shares of the company's stock in a transaction on Thursday, March 14th. The shares were sold at an average price of $956.47, for a total value of $5,531,266.01. Following the completion of the transaction, the executive vice president now directly owns 48,306 shares of the company's stock, valued at approximately $46,203,239.82. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. In other news, EVP Andrew J. Murphy sold 5,783 shares of the stock in a transaction dated Thursday, March 14th. The shares were sold at an average price of $956.47, for a total transaction of $5,531,266.01. Following the completion of the transaction, the executive vice president now directly owns 48,306 shares in the company, valued at approximately $46,203,239.82. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, EVP Marion Mccourt sold 358 shares of the stock in a transaction dated Friday, March 1st. The stock was sold at an average price of $967.50, for a total transaction of $346,365.00. Following the transaction, the executive vice president now owns 13,431 shares of the company's stock, valued at $12,994,492.50. The disclosure for this sale can be found here. Insiders sold a total of 13,729 shares of company stock worth $13,124,641 in the last quarter. Corporate insiders own 8.83% of the company's stock.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.